Weight change associated with antiepileptic drugs

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 7, 2013, Pages 796-799

  Pickrell, WilliamOwen ^a   Lacey, Arron S ^a   Thomas, Rhys H ^a   Smith, Philip E M ^a,b   Rees, Mark I ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; TOPIRAMATE; VALPROIC ACID;

ADULT; ARTICLE; DISEASE ASSOCIATION; DRUG SAFETY; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; UNITED KINGDOM; WEIGHT CHANGE; WEIGHT REDUCTION;

EID: 84878767623     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-303688     Document Type: Article

References (17)

1. Joint Epilepsy Council of the UK and Ireland. Epilepsy prevalence, incidence and other statistics. December 2001. http://www.jointepilepsycouncil. org.uk (accessed 29 November 2012).
2. Thomas RH, Hammond CL, Bodger OG, et al. Identifying and prioritising epilepsy treatment uncertainties. J Neurol Neurosurg Psychiatry 2010;81:918-21.
3. Ben-Menachem E. Weight issues for people with epilepsy - a review. Epilepsia 2007;48:42-5. (Pubitemid 350198229)
4. Ford DV, Jones KH, Verplancke JP, et al. The SAIL Databank: building a national architecture for e-health research and evaluation. BMC Health Serv Res 2009;9:157.
5. Lyons RA, Jones KH, John G, et al. The SAIL databank: linking multiple health and social care datasets. BMC Med Inform Decis Mak 2009;9:3.
6. Verrotti A, D'Egidio C, Mohn A, et al. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev 2011;12:e32-43.
7. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurol 2001;56:172-7. (Pubitemid 32095356)
8. Verrotti A, Scaparrotta A, Agostinelli S, et al. Topiramate-induced weight loss: a review. Epilepsy Res 2011;95:189-99.
9. Devinsky O, Vuong A, Hammer A, et al. Stable weight during lamotrigine therapy: a review of 32 studies. Neurol 2000;54:973-5. (Pubitemid 30111362)
10. Hogan RE, Bertrand ME, Deaton RL, et al. Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. Epilepsy Res 2000;41:23-8. (Pubitemid 30621398)
11. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264. N Engl J Med 1992;327:765-71.
12. Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003;107:165-75. (Pubitemid 36398991)
13. Gidal BE, Sheth RD, Magnus L, et al. Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials. Epilepsy Res 2003;56:121-6. (Pubitemid 37464925)
14. Kaminski RM, Gillard M, Klitgaard H. Targeting SV2A for discovery of antiepileptic drugs. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV.ed. Jasper 's basic mechanisms of the epilepsies (Internet). 4th edn. Bethesda(MD): National Center for Biotechnology Information (US), 2012.
15. Iezzi M, Theander S, Janz R, et al. SV2A and SV2C are not vesicular Ca2+ transporters but control glucose-evoked granule recruitment. J Cell Sci. 2005;118:5647-60. (Pubitemid 43079303)
16. Kotsopoulos IA, Van MT, Kessels FG, et al. Systematic Review and Meta-analysis of Incidence Studies of Epilepsy and Unprovoked Seizures. Epilepsia 2002;43:1402-9. (Pubitemid 35365000)
17. Rowlands S, Moser K. Consultation rates from the General Practice Research Database. Br J Gen Pract 2002;52:658-60.